Meeting
2021 ASCO Annual Meeting
AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).
Authors
Helen J. Ross
Thoracic Oncology, Phoenix, AZ
Helen J. Ross , David E. Kozono , James John Urbanic , Terence Marques Williams , Carter DuFrane , Ilze Bara , Katja Schulze , Jane Michelle Brockman , Xiaofei F. Wang , Junheng Gao , Everett E. Vokes , Tom Stinchcombe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03102242
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8513)
DOI
10.1200/JCO.2021.39.15_suppl.8513
Abstract #
8513
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).
First Author: Helen J. Ross
Poster
2018 ASCO Annual Meeting
Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.
First Author: Helen J. Ross
Poster
2022 ASCO Annual Meeting
Checkpoint inhibitor consolidation after definitive chemoradiation for stage III non–small cell lung cancer: Real-world experience in a large academic health system.
First Author: Nikhil Yegya-Raman
Poster
2021 ASCO Annual Meeting
Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.
First Author: Alex K. Bryant